Cargando…

Biologics for Psoriasis during the COVID-19 Pandemic

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamiya, Koji, Komine, Mayumi, Ohtsuki, Mamitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036429/
https://www.ncbi.nlm.nih.gov/pubmed/33808455
http://dx.doi.org/10.3390/jcm10071390
_version_ 1783676908058181632
author Kamiya, Koji
Komine, Mayumi
Ohtsuki, Mamitaro
author_facet Kamiya, Koji
Komine, Mayumi
Ohtsuki, Mamitaro
author_sort Kamiya, Koji
collection PubMed
description Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.
format Online
Article
Text
id pubmed-8036429
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80364292021-04-12 Biologics for Psoriasis during the COVID-19 Pandemic Kamiya, Koji Komine, Mayumi Ohtsuki, Mamitaro J Clin Med Review Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19. MDPI 2021-03-30 /pmc/articles/PMC8036429/ /pubmed/33808455 http://dx.doi.org/10.3390/jcm10071390 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kamiya, Koji
Komine, Mayumi
Ohtsuki, Mamitaro
Biologics for Psoriasis during the COVID-19 Pandemic
title Biologics for Psoriasis during the COVID-19 Pandemic
title_full Biologics for Psoriasis during the COVID-19 Pandemic
title_fullStr Biologics for Psoriasis during the COVID-19 Pandemic
title_full_unstemmed Biologics for Psoriasis during the COVID-19 Pandemic
title_short Biologics for Psoriasis during the COVID-19 Pandemic
title_sort biologics for psoriasis during the covid-19 pandemic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036429/
https://www.ncbi.nlm.nih.gov/pubmed/33808455
http://dx.doi.org/10.3390/jcm10071390
work_keys_str_mv AT kamiyakoji biologicsforpsoriasisduringthecovid19pandemic
AT kominemayumi biologicsforpsoriasisduringthecovid19pandemic
AT ohtsukimamitaro biologicsforpsoriasisduringthecovid19pandemic